Mavrilimumab
Mavrilimumab
Mavrilimumab (pronunciation: mav-ri-li-mu-mab) is a monoclonal antibody designed for the treatment of rheumatoid arthritis. It is an investigational drug that targets and inhibits the granulocyte macrophage colony-stimulating factor receptor alpha (GM-CSFRα), a protein that plays a crucial role in the pathogenesis of inflammatory diseases.
Etymology
The name "Mavrilimumab" follows the INN naming convention for monoclonal antibodies. The prefix "Mavri-" is arbitrary, the infix "-lim-" signifies immunomodulating, and the suffix "-mab" indicates it is a monoclonal antibody.
Mechanism of Action
Mavrilimumab works by binding to the alpha chain of the GM-CSFRα, blocking the binding of the granulocyte macrophage colony-stimulating factor (GM-CSF) to its receptor. This inhibits the pro-inflammatory signaling cascade, reducing inflammation and potentially slowing the progression of diseases like rheumatoid arthritis.
Clinical Trials
Mavrilimumab has undergone several clinical trials to evaluate its safety and efficacy in treating rheumatoid arthritis. It has shown promise in reducing the signs and symptoms of the disease, improving physical function, and slowing the progression of joint damage.
Related Terms
- Monoclonal antibody
- Rheumatoid arthritis
- Granulocyte macrophage colony-stimulating factor receptor alpha
- Granulocyte macrophage colony-stimulating factor
- Clinical trial
External links
- Medical encyclopedia article on Mavrilimumab
- Wikipedia's article - Mavrilimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski